With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135616-36-3,(S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine,as a common compound, the synthetic route is as follows.
Reference Example 1 [(R,R)-N,N’-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine] (hereinafter, referred to as L3 when it is a ligand of a complex) (10.9 g, 20.0 mmol) was dissolved in dichloromethane (80mL), the solution was added to a methanol solution (80 mL) of cobalt acetate tetrahydrate (5.98 g, 24.0 mmol), the mixture was stirred at room temperature for 15 minutes, and as a result, a red solid was precipitated. After stirred at 0 C. for 30 minutes, the red solid was collected and dried to obtain Co(L3) (11.6 g, red solid) (yield: 96%)., 135616-36-3
The synthetic route of 135616-36-3 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Japan Science and Technology Agency; Takasago International Corporation; US2006/173210; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI